Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
1999-06-07
2002-06-18
Swartz, Rodney P (Department: 1645)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C424S009100, C424S130100, C424S138100, C435S005000, C435S007920, C435S007930, C436S811000
Reexamination Certificate
active
06406860
ABSTRACT:
BACKGROUND OF THE INVENTION
The transmissible spongiform encephalopathies (TSE) constitute a group of neurodegenerative diseases. In humans these diseases include Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Scheinker syndrome, Fatal Familial Insomnia, and Kuru (see, e.g.,
Harrison's Principles of Internal Medicine
, Isselbacher et al., eds., McGraw-Hill, Inc. New York, (1994); Medori et al. 1992
N. Engl. J. Med
., 326: 444-9.). In animals the TSE's include sheep scrapie, bovine spongiform encephalopathy, transmissible mink encephalopathy, and chronic wasting disease of captive mule deer and elk (Gajdusek, (1990)
Subacute Spongiform Encephalopathies: Transmissible Cerebral Amyloidoses Caused by Unconventional Viruses
. Pp. 2289-2324 In:
Virology
, Fields, ed. New York: Raven Press, Ltd.). Transmissible spongiform encephalopathies are characterized by the same hallmarks: a spongiform degeneration, reactive gliosis in the cortical and subcortical gray matters of the brain, and transmission when experimentally inoculated into laboratory animals including primates, rodents, and transgenic mice.
Recently, the rapid spread of bovine spongiform encephalopathy and its correlation with elevated occurrence of spongiform encephalophathies in humans has lead to a significant increase of interest in the detection of transmissible spongiform encephalopathies in non-human mammals. The tragic consequences of accidental transmission of these diseases (see, e.g., Gajdusek,
Infectious Amyloids
, and Prusiner Prions In
Fields Virology
. Fields, et al., eds. Lippincott-Ravin, Pub. Philadelphia (1996); Brown et al. (1992)
Lancet
, 340: 24-27), and the decontamination difficulties (Asher et al. (1986) pages 59-71 In:
Laboratory Safety: Principles and Practices
, Miller ed.
Am. Soc. Microb
.), and recent concern about bovine spongiform encephalopathy (
British Med. J
. 1995; 311: 1415-1421) underlie the urgency of having a diagnostic test that would identify humans and animals with transmissible spongiform encephalopathies.
Definitive premortem diagnosis of these transmissible diseases can only be made histopathologically; however, biopsy of brain tissue is not an ideal method due to risks to animals, patients, and health care personnel. Moreover, lesions can be missed because of the patchy nature of the pathological process.
Measurement of most cerebrospinal fluid (CSF) proteins that have been implicated as pre-mortem markers of Creutzfeldt-Jakob disease have not been very useful diagnostically. These include neuron-specific enolase (NSE) (Jimi et al. (1992)
Lancet
, 211: 37-46; and Zer et al. (1995)
Lancet
, 345: 160-9-1610), S-100b protein (Jimi et al., supra), brain-type isozyme of creatine kinase (Jimi et al., supra), GTP binding protein G0 (Jimi et al., supra), ubiquitin (Manaka et al. (1992)
Neurosci. Letts
. 139: 47-49), and lactic acid (Awerbuch et al. (1985)
Internat. J. Neurosci
., 42: 1-5).
However, two useful marker proteins, designated proteins 130 and 131, were discovered by two-dimensional electrophoresis (2DE) and silver staining surveys of cerebrospinal fluid (CSF) (see, e.g., Harrington et al. (1986)
N. Engl. J. Med
., 315: 279-283 and U.S. Pat. No. 4,892,814). These markers were shown to have very high sensitivity (21/21) and specificity (515/520) in the diagnosis of Creutzfeldt-Jacob disease, and this test has been extremely useful in the premortem diagnosis of several difficult cases (see, e.g., Croxson et al. (1988)
Neurology
38: 1128-30; Blisard et al. (1990)
J. Neurological Sci
., 99: 75-81; Marzewski et al., (1988)
Neurology
, 38: 1131-33; Macario et al. (1991)
British Med J
. 302: 1149). The only other disease in which these proteins were found was herpes encephalitis which is easily distinguished on clinical presentation. Testing for these markers, however, has required the two-dimensional electrophoresis (2DE) technique, which is cumbersome and time-consuming. Thus, despite the very high correlation of these marker proteins with the disease, the two-dimensional electrophoresis biochemical test has not become practical for clinical use.
SUMMARY OF THE INVENTION
This invention provides improved assays for the detection of transmissible spongiform encephalopathies (TSEs) in humans and non-human mammals. The invention is premised, in part, on the surprising discovery that elevated levels of 14-3-3 protein(s) in cerebrospinal fluid are indicative of (highly correlated with) transmissible spongiform encephalopathies (e.g., Creutzfeldt-Jacob disease in humans and bovine spongiform encephalopathy (mad cow disease) in bovines).
In a preferred embodiment this invention provides a method of detecting a transmissible spongiform encephalopathy (TSE) in a human or in a non-human mammal. Preferred transmissible spongiform encephalopathies include Creutzfeldt-Jakob Disease in the case of a human, bovine spongiform encephalopathy (BSE or mad cow disease) in the case of a bovine, and scrapie in the case of sheep.
The methods of this invention involve detecting the presence or absence, or quantifying, a 14-3-3 protein in cerebrospinal fluid of the human or non-human mammal: In the case of a human, detection of the 14-3-3 protein is preferably by use of an immunoassay (e.g., Western Blot assay or Sandwich assay). In the case of a non-human mammal, detection is by any convenient means, preferably a two-dimensional electrophoresis or by use of an immune assay (e.g., Western Blot assay or Sandwich assay). When applied to a human, the method can further comprise determining that the human does not suffer from herpes simplex encephalitis.
Preferred immunoassays use an anti-14-3-3 antibody. The antibody can be polyclonal or monoclonal, with polyclonal antibodies being more preferred. Particularly preferred assay formats include Western Blot assays and antigen capture (e.g., Sandwich) assays.
Definitions
The following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein.
The term “14-3-3 protein” is used herein to refer to members of the 14-3-3 class of proteins as it is commonly known to those of skill in the art (see, e.g., Ichimura et al. (1988)
Proc. Nat'l. Acad. Sci. USA
85:7084-7088, Zupan et al. (1992)
J. Biol. Chem
., 267: 8707-8710; Aitken et al. (1992)
Trends. Biochem. Sci
., 17: 498-501; Burbelo et al. (1995)
Current Biology
,5: 95-96; Robinson et al. (1994)
Biochem. J
. 299: 853-861; Ichimura et al. (1988)
Proc. Nat'l. Acad. Sci. USA
, 85: 7084-7088; and Morgan et al. (1992)
Nature
, 355: 833-836). Assays that detect 14-3-3 are intended to detect the level of endogenous (native) 14-3-3 present in subject biological sample (e.g., CSF). However, exogenous 14-3-3 (14-3-3 protein from a source extrinsic to the biological sample) may be added to various assays to provide a label or to compete with the native 14-3-3 in binding to an anti-14-3-3 antibody. One of skill will appreciate that a 14-3-3 mimetic may be used in place of exogenous 14-3-3 in this context. An “14-3-3 minetic”, as used herein, refers to a molecule that bears one or more 14-3-3 epitopes such that it is specifically bound by an antibody that specifically binds native 14-3-3.
The phrase “diagnostic of a transmissible spongiform encephalopathy” is used herein to refer to a marker or assay that is indicative of the presence or predicts the ultimate onset of a transmissible spongiform encephalopathy. However, it will be appreciated by one of skill in the art, that all assays exhibit a certain level of false positives and false negatives. Even where a positive result in an assay is not invariably associated with the ultimate onset of the encephalopathy (i.e. where there are some false positives), the result is valuable as it results in more careful monitoring of the patient or animal and the institution of appropriate containment procedures thus reducing risk of infection and transmission through the population. An assay is diagnostic of a transmissible spongiform encephalopathy where detection
Gibbs, Jr. Clarence J.
Harrington Michael G.
Hsich Gary
Kenney Kimbra
Swartz Rodney P
The United States of America as represented by the Department of
Townsend and Townsend / and Crew LLP
LandOfFree
Method of detecting transmissible spongiform encephalopathies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of detecting transmissible spongiform encephalopathies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of detecting transmissible spongiform encephalopathies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2907559